The study investigates the link between elevated liver enzymes (AST and ALT) and maternal and neonatal outcomes in patients diagnosed with preeclampsia with severe features.
It utilizes a retrospective cohort from Oregon Health & Science University, focusing on patients who delivered after 23 weeks’ gestation between 2013 and 2018.
The results indicate that among 319 preeclampsia patients, those with elevated liver enzymes did not experience significantly different adverse maternal outcomes compared to those with normal levels, suggesting that elevated liver enzymes may not be a definitive indicator of increased maternal risk.